Comparing Precigen (PGEN) & Its Competitors
Precigen (NASDAQ: PGEN) is one of 35 publicly-traded companies in the “Commercial physical research” industry, but how does it compare to its rivals? We will compare Precigen to similar companies based on the strength of its dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.
Earnings & Valuation
This table compares Precigen and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Precigen||$90.72 million||-$322.32 million||-3.68|
|Precigen Competitors||$1.24 billion||$44.58 million||9.28|
Volatility and Risk
Precigen has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, Precigen’s rivals have a beta of 10.27, suggesting that their average share price is 927% more volatile than the S&P 500.
This is a summary of current ratings and price targets for Precigen and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Commercial physical research” companies have a potential upside of 51.81%. Given Precigen’s rivals higher probable upside, analysts clearly believe Precigen has less favorable growth aspects than its rivals.
This table compares Precigen and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
74.1% of Precigen shares are held by institutional investors. Comparatively, 51.1% of shares of all “Commercial physical research” companies are held by institutional investors. 44.0% of Precigen shares are held by company insiders. Comparatively, 17.4% of shares of all “Commercial physical research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Precigen rivals beat Precigen on 8 of the 10 factors compared.
Precigen, Inc. engages in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of artificial additives; genetically engineered swine for medical and genetic research; commercial aquaculture products; and preservation and cloning technologies. The company also offers UltraVector platform that enables design and assembly of gene programs that facilitate control over the quality, function, and performance of living cells; and RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression. In addition, it provides AttSite Recombinases, which allows stable, targeted gene integration and expression; LEAP automated platform to identify and purify cells of interest, such as antibody expressing cells and stem cells; ActoBiotics platform for targeted in situ expression of proteins and peptides from engineered microbes; and AdenoVerse technology platform for tissue specificity and target selection. The company serves the health, food, energy, and environment markets. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Genopaver, LLC; Fibrocell Science, Inc.; Persea Bio, LLC; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Wellness. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.